Remus Pharmaceuticals's cash flow for dividends for the
six
months ended in Mar. 2026 was ₹0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Remus Pharmaceuticals's quarterly payment of dividends
declined
from Mar. 2025 (₹-6 Mil) to Sep. 2025 (₹0 Mil) but then
stayed the same
from Sep. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).
Remus Pharmaceuticals's annual payment of dividends
increased
from Mar. 2024 (₹-6 Mil) to Mar. 2025 (₹-12 Mil) but then
stayed the same
from Mar. 2025 (₹-12 Mil) to Mar. 2026 (₹-12 Mil).
Remus Pharmaceuticals Cash Flow for Dividends Related Terms
Remus Pharmaceuticals Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals Cash Flow for Dividends Chart
Remus Pharmaceuticals Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of ₹0 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Cash Flow for Dividends of ₹0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Cash Flow for Dividends too high?
Remus Pharmaceuticals' current Cash Flow for Dividends is ₹0 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Cash Flow for Dividends compare to MCK and CAH?
Remus Pharmaceuticals' Cash Flow for Dividends of ₹0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Distribution company?
A good Cash Flow for Dividends depends on the Medical Distribution industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Cash Flow for Dividends is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current Cash Flow for Dividends is ₹0 Mil. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Cash Flow for Dividends is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Cash Flow for Dividends: ₹0 Mil
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
